Rina Sor

Abstract LB406: Active RAS inhibition intercepts pancreas cancer in mice

Minh T. Than, Lucie Dequiedt, Rina Sor, Shreya Nair et autres

Abstract Cancer interception is a clinical approach to eliminate pre-malignant lesions, distinct from approaches to treat invasive cancer, but effective strategies in pancreatic ductal adenocarcinoma (PDAC) remain to be identified. Conceptually, interception strategies should target precancerous lesions such as pancreatic intraepithelial neoplasia …

us (code pays fourni par la source)

Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment

Vivien I. Maltez, Charu Arora, Kyle P. Gribbin, Breanna P Caruso et autres

us (code pays fourni par la source)

Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma

Minh T. Than, Lucie Dequiedt, Rina Sor, Shreya Nair et autres

Transformation of pancreatic epithelial cells to malignant pancreatic ductal adenocarcinoma (PDAC) typically involves the progression of precancerous pancreatic intraepithelial neoplasia (PanINs) bearing oncogenic KRAS mutations. Here, we tested the impact of PDAC interception using either RAS(ON) multiselective or RAS(ON) G12D-selective pharmacological inhibitors …

us (code pays fourni par la source)

Supplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

Supplementary Figures and Table with legend arranged in a single presentable package

Supplementary Table from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

Antibody lists

Supplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

Effects of MRTX1133 in KPC/Y and subcutaneous models

Supplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro

Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

MRTX1133 exerts in vivo effects early in treatment

Supplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

MRTX1133 elicits changes in the tumor stroma and vasculature

Supplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

MRTX1133 reduces metastatic burden in a tail vein model

Supplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah C. Cheng, Nune Markosyan, Rina Sor et autres

KRASG12D inhibition alters the tumor immune microenvironment

Data from T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Margo Orlen, William P. Vostrejs, Rina Sor, Jayne C. McDevitt et autres

Abstract Activating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment, rendering PDAC tumors insensitive to immunotherapy. RAS(ON) multi-selective inhibitors, such as daraxonrasib (RMC-6236) and RMC-7977, target the active state …